Biocon Biologics’ Malaysian subsidiary secured a six-month extension to its insulin supply contract with the Malaysian government, continuing a nearly decade-long partnership. The extension, effective April 2025, builds on a 2022 three-year agreement.

• Contract extended six months to October 2025.
• Biocon Biologics has supplied insulin for ~10 years.
• Manufacturing occurs at the Johor facility in Malaysia.